ASCO 2026: frontMIND trial – improved progression free survival outcomes for aggressive B-cell lymphoma
Original story from the ASCO Annual Meeting
The results from the Phase III frontMIND trial show that adding tafasitamab and lenalidomide to R-CHOP for first-line treatment can reduce tumor progression in people with aggressive diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). The results are notable because the population included in the trial had high-intermediate risk and high-risk disease, which typically leads to poor outcomes. The research will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 to June 2 in Chicago.
Study at a glance
| Focus | Improvements in first-line therapy for high-intermediate and high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) |
| Population | 899 people in North and South America, Europe, and Asia |
| Main Takeaway | The addition of tafasitamab and lenalidomide to R-CHOP reduced the risk of disease progression or death in patients with high-risk DLBCL or HGBL, compared to R-CHOP alone. |
| Significance | DLBCL and HGBL are both aggressive forms of non-Hodgkin lymphoma. DLBCL is the most common form, accounting for about 24,000 diagnoses each year. HGBL accounts for about 1,600 diagnoses per year. |
| About 20% of people with DLBCL have high-intermediate risk disease and 15% have high-risk disease. | |
| Most people with DLBCL or HGBL get a combination of 5 medicines called R-CHOP. In about 40% of people with DLBCL who receive R-CHOP, the cancer either continues to grow or recurs. There is less data for HGBL, but it is considered more aggressive than DLBCL. | |
| The phase II L-MIND trial showed that in relapsed or refractory DLBCL, treating with the immunotherapies tafasitamab and lenalidomide can reduce or eliminate tumors. | |
| The researchers conducted this study to see if these two medicines given with R-CHOP as a first-line treatment can prevent the growth of DLBCL or HGBL more effectively than R-CHOP alone. |
ASCO perspective quote
“The frontMIND study represents only the second Phase III randomized controlled trial in the last 25 years to demonstrate an improvement in primary efficacy outcome compared to the long-time global standard of care R-CHOP for patients with newly diagnosed diffuse large B-cell lymphoma. Importantly, this improvement in progression-free survival is likely to lead to an improvement in long-term curative outcomes for patients with newly diagnosed diffuse large B-cell lymphoma,” said Krish Patel, MD, Executive Director of Hematologic Cancer Research at Sarah Cannon Research Institute and an ASCO Expert in lymphoma.
About the study
“While treatment for diffuse large B-cell lymphoma has improved in the last couple of years, many patients, especially those with high-risk disease, still face poor prognoses. The frontMIND study is significant as it is one of the few large phase 3 trials in first-line diffuse large B-cell lymphoma in which adding a therapy to R-CHOP improved clinical outcomes compared to R-CHOP alone, the standard regimen for over 20 years,” said lead study author Georg Lenz, MD, University Hospital Münster, Münster, Germany.
The frontMIND trial tested whether adding tafasitamab and lenalidomide to R-CHOP was a better first-line therapy than R-CHOP alone, particularly for people with higher risk DLBCL or HGBL and a poor prognosis. The trial included 899 people with high-intermediate or high-risk DLBCL or HGBL. The median age of participants was 65, and just over half were male. Participants were divided into 2 groups:
- 448 were assigned to receive tafasitamab and lenalidomide in addition to R-CHOP (tafasitamab and lenalidomide group).
- 451 were assigned to receive placebo and R-CHOP (control group).
Key findings
- With a median follow-up time of 35.2 months, treatment with tafasitamab, lenalidomide, and R-CHOP reduced the risk of progression by 25%, compared to treatment with R-CHOP alone. The 3-year progression-free survival (PFS) was 67.3% in the tafasitamab and lenalidomide group, compared to 60.7% in the control group.
- Among participants whose diagnosis was centrally confirmed (773 of 899 participants), the combination treatment reduced the risk of progression by 32%.
- The authors report that the PFS benefit was seen in both ABC-type and GCB-type DLBCL. Data will be presented at the meeting.
Complete response (CR) and overall response rate (ORR) were similar in the two groups:- CR was achieved in 65.2% of participants in both groups.
- ORR was 80.4% in the tafasitamab and lenalidomide group vs. 76.1% in the control group.
- The difference in overall survival was not significant (81.7% in the tafasitamab and lenalidomide group vs. 78.9% in the control group at the time of reporting) but will continue to be monitored.
After starting treatment, more people in the tafasitamab and lenalidomide group experienced grade 3 and higher adverse events than in the control group—86.7% vs. 76.1%—but the issues were considered manageable. Infections and low numbers of white or red blood cells were more common in the tafasitamab and lenalidomide group than in the control group. Adverse events led 25.7% of the tafasitamab and lenalidomide group and 17.9% of the control group to discontinue part of the treatment. About 5% in both groups stopped treatment altogether.
These data will be used to support the regulatory submissions seeking approval of tafasitamab and lenalidomide with R-CHOP as a first-line treatment in adults with newly diagnosed DLBCL and HGBL.
This study was funded by Incyte Corporation.
This article has been republished from the following materials. Material may have been edited for length and house style. For further information, please contact the cited source. Our press release publishing policy can be accessed here.